Peptalk← All compounds

Sleep & Recovery

DSIP (Delta Sleep-Inducing Peptide)

Also known as Delta Sleep-Inducing Peptide · Emideltide · CAS 62568-57-4

PreliminarySubcutaneous injectionIntravenous infusion (research settings)Intranasal (investigational)Not an FDA-approved drug; it has only been used investigationally and is not an approved pharmaceutical product. On April 15, 2026 the FDA removed DSIP (Emideltide) from Category 2 of the Section 503A bulk drug substances list, but removal does not authorize compounding — it has not been placed on the 503A authorized bulks list, and a Pharmacy Compounding Advisory Committee (PCAC) review was scheduled for July 24, 2026 to evaluate it further. As of mid-2026, compounding pharmacies are not authorized to produce it pending that outcome. DSIP is not explicitly named on the WADA Prohibited List, but as a non-approved substance it can fall under WADA's catch-all provision for substances with no current approval, so athletes should verify current status before use.

DSIP is a small naturally occurring neuropeptide of nine amino acids (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu), first isolated in the 1970s from the cerebral venous blood of sleeping rabbits and later identified across many species and human tissues. Its precise mechanism remains poorly characterized; proposed pathways include modulation of glutamatergic (NMDA) and GABA-ergic signaling, interaction with the MAPK cascade, and links to glucocorticoid and HPA-axis activity, but no specific receptor has been definitively established. Human sleep research consists mostly of small, older, and methodologically limited trials that report conflicting outcomes, and its very short measured half-life complicates interpretation. Beyond sleep, it has been examined in preclinical and early clinical work for stress, pain, and related endpoints, but the overall evidence base remains thin and largely preliminary. Long-term safety has not been established in controlled clinical research.

Studied / used for

  • Studied for sleep regulation and disturbed-sleep parameters such as sleep latency and efficiency
  • Investigated for stress response and stress-limiting effects
  • Investigated for pain perception and analgesic activity
  • Investigated in early clinical work for opioid/drug-withdrawal symptoms
  • Explored preclinically for effects on temperature regulation and seizure activity

Commonly reported side effects

  • Injection-site reactions such as redness or discomfort commonly reported
  • Headache commonly reported
  • Transient dizziness or lightheadedness commonly reported
  • Fatigue or grogginess commonly reported
  • Nausea occasionally reported
Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds